期刊文献+

PKM2基因对CD44^+肺癌干细胞增殖及耐药性的影响 被引量:1

Effect of pkm2 Gene on Proliferation and Drug Resistance in CD44^+ Lung Cancer Stem Cells
下载PDF
导出
摘要 目的观察转染后CD44+肺癌干细胞内PKM2基因的表达变化及其对CD44+肺癌干细胞增殖、耐药性的影响。方法将A549肺癌细胞株继代培养后,采取免疫磁珠细胞分选法,通过Auto MACS仪器,分选出CD44+细胞。实验分为实验组和对照组,将人工合成的针对PKM2基因的siRNA片段通过Lipofectamine 2000转染细胞,分别采用实时荧光定量聚合酶链反应(real-time quantitative PCR,qRT-PCR)和Western blot法检测各组细胞中PKM2的mRNA和蛋白质的表达量,细胞免疫组化染色分析CD44及PKM2表达,并采用MTT法检测各组细胞的增殖活力。药性敏感性试验:在培养基内添加不同浓度化疗药物DDP,并通过MTT assay测试细胞的生长及增殖速度。结果 CD44+肺癌干细胞转染PKM2 siRNA后,CD44+肺癌干细胞中PKM2 mRNA及蛋白表达减弱(P<0.05),细胞增殖能力减弱,抗肿瘤药物耐药性降低。结论 PKM2对CD44+肺癌干细胞的增殖起促进作用,同时具有增强抗肿瘤药物耐药性的作用。 Objective To investigate the expression of PKM2 and its effect on the proliferation and drug resistance in CD44+lung cancer stem cells. Methods Lung cancer A549 cells were separated into CD44+cells and CD44+cells by the immunomagnetic beads method through Auto MACS instrument,and then the PKM2 siRNA was transfected into CD44+lung cancer stem cells by Lipofectamine 2000. The experimental group and the control group were included in the study. qRT-PCR and western blot were used to measure the PKM2 expression at mRNA and protein levels,respectively. The cell proliferation was assessed by MTT assay. Drug sensitivity test: different chemotherapy drugs solubility of DDP were added into the culture medium,and then the cell proliferation was assessed by MTT assay. Results PKM2 siRNA was transfected into CD44+lung cancer stem cells,the expression of PKM2 mRNA and protein in CD44+cells decreased significantly( P < 0. 05),cell proliferation ability decreased,and anti-tumor drug resistance was reduced in CD44+cells. Conclusion PKM2 plays an important role in promoting the proliferation of CD44+lung cancer stem cells and enhancing the anti-tumor drug resistance.
出处 《实用癌症杂志》 2015年第5期641-644,共4页 The Practical Journal of Cancer
关键词 肺癌干细胞 PKM2 增殖 耐药性 Lung cancer stem cells PKM2 Proliferation Drug resistance
  • 相关文献

参考文献12

  • 1Kumar Yogesh,Mazurek Sybille,Yang Shiyu,Failing Klaus,Winslet Marc,Fuller Barry,Davidson Brian R.In vivo factors influencing tumour M2-pyruvate kinase level in human pancreatic cancer cell lines. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine . 2010
  • 2Hardt P D,Toepler M,Ngoumou B,Rupp J,Kloer H U.Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening. Anticancer Research . 2003
  • 3Hua‐shanShi,DanLi,JingZhang,Yong‐shengWang,LiYang,Hai‐longZhang,Xian‐huoWang,BoMu,WeiWang,YuMa,Fu‐chunGuo,Yu‐quanWei.Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice[J]. Cancer Science . 2010 (6)
  • 4Emily C. Ferguson,Jeffrey C. Rathmell.New roles for pyruvate kinase M2: working out the Warburg effect[J]. Trends in Biochemical Sciences . 2008 (8)
  • 5MAZLUREK S,BOSCKHEK CB,HUGO F,et al.Pgrubate Kinase type M2 and its role in tumor growth and spreeding. Sen in Cancer Biol . 2005
  • 6Mazurek Sybille,Eigenbrodt Erich.The tumor metabolome. Anticancer Research . 2003
  • 7Luo Z,Wu RR,Lv L,et al.Prognostic value of CD44 expression in non-small cell lung cancer:a systematic review. Int J Clin Exp Pathol . 2014
  • 8Weiwei Yang,Zhimin Lu.Regulation and function of pyruvate kinase M2 in cancer[J]. Cancer Letters . 2013
  • 9Barbara Chaneton,Eyal Gottlieb.Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer[J]. Trends in Biochemical Sciences . 2012 (8)
  • 10Christofk Heather R,Vander Heiden Matthew G,Harris Marian H,Ramanathan Arvind,Gerszten Robert E,Wei Ru,Fleming Mark D,Schreiber Stuart L,Cantley Lewis C.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature . 2008

二级参考文献7

  • 1Sturgeon CM. Carcinoembryonic antigen and related glycoproteins as tumor markers. Trends Biochem Sci,1979,4:121-123.
  • 2Oremek GM,Teigelkamp S,Kramer W,et al. The pyruvate kinase isoenzyme tumor M2(Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res,1999,19:2599-2601.
  • 3Oremek GM,Eigenbrodt E,Radle J,et al. Value of the serum levels of the tumor marker Tu M2-PK in pancreatic cancer. Anticancer Res,1997,17:3031-3033.
  • 4Schneider J,Velcovsky HG,Morr H,et al. Comparison of the tumor markers tumor M2-PK,CEA,CYFRA-21, NSE and SCC in the diagnosis of lung cancer. Anticancer Res,2000,20:5053-5058.
  • 5Hugo F,Fischer G,Eigenbrodt E. Quantitative detection of tumor M2-PK in serum and plasma. Anticancer Res,1999,19:2753-2757.
  • 6Eigenbrodt E,Basenau D,Holthusen S,et al. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res,1997,17:3153-3156.
  • 7Eigenbrodt E,Reinacher M,Scheefers-Borchel U,et al. Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Cri Rev Oncog,1992,3:91-115.

共引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部